Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report 2025

The ribonucleic acid (RNA)-based oncolytic therapy market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.12 billion in 2025 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period is attributed to the increasing prevalence of cancer, rising investment in healthcare infrastructure, growing awareness of targeted therapies, expansion of clinical trial programs, and higher government funding for oncology research.

The ribonucleic acid (RNA)-based oncolytic therapy market size is expected to see rapid growth in the next few years. It will grow to $4.17 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period is driven by greater adoption of RNA-based therapies, increased focus on immuno-oncology, rising biotechnology collaborations, expansion of advanced manufacturing facilities, and improved access to precision medicine. Key trends in the forecast period include technological advancements, progress in viral vector design, increased investment in research and development, innovation in delivery systems, and the development of combination therapy approaches.

The increasing adoption of personalized medicine is expected to drive growth in the RNA-based oncolytic therapy market. Personalized medicine involves tailoring medical treatments according to an individual’s genetic profile, which enhances treatment effectiveness while minimizing side effects. This approach is being embraced more widely as healthcare providers and institutions recognize its potential to improve patient outcomes through targeted therapies and precise diagnostics. RNA-based oncolytic therapy supports this trend by providing targeted, patient-specific cancer treatments that align with personalized medicine principles. For example, in February 2024, the Personalized Medicine Coalition, a United States-based advocacy organization for tailored treatments, reported that the FDA approved sixteen new personalized therapies for rare disease patients in 2023, a notable increase from six approvals in 2022. Consequently, the growing use of personalized medicine is propelling the RNA-based oncolytic therapy market forward.

Leading companies in the RNA-based oncolytic therapy market are advancing technologies such as synthetic messenger RNA (mRNA) to improve tumor targeting, stimulate immune responses, and achieve more precise and lasting cancer treatment results. Synthetic mRNA technology is a biotech method that creates and delivers artificial mRNA sequences to instruct cells to produce specific therapeutic proteins to treat diseases, including cancer. For example, in June 2024, CSPC Pharmaceutical Group Limited, a pharmaceutical company based in China, received regulatory clearance to begin clinical trials of SYS6020, a synthetic mRNA-based cancer cell therapy. This milestone marks a significant step in China’s mRNA therapeutic field. SYS6020 uses mRNA-lipid nanoparticle technology to selectively attack and destroy myeloma cancer cells with minimal side effects, and it shows promise for treating certain autoimmune disorders.

In June 2023, Charles River Laboratories International, Inc., a US contract research organization, formed a strategic partnership with Curigin Co., Ltd. to develop oncolytic RNA interference (RNAi) gene therapies. The collaboration aims to accelerate the development and production of Curigin’s RNAi-based oncolytic gene therapies by utilizing Charles River’s contract development and manufacturing expertise to support both preclinical and clinical studies. Curigin Co., Ltd. is a South Korea-based biotech firm specializing in RNAi oncolytic gene therapies for cancer treatment.

Major players in the ribonucleic acid (RNA)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.

North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ribonucleic acid (RNA)-based oncolytic therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ribonucleic acid (RNA)-based oncolytic therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Ribonucleic acid (RNA)-based oncolytic therapy is a cancer treatment that employs engineered RNA viruses to selectively infect and destroy tumor cells. These viruses replicate within cancer cells, leading to cell death and the release of tumor antigens. This process also activates the immune system to target remaining cancer cells, enhancing overall anti-tumor effectiveness.

The primary therapy types of ribonucleic acid (RNA)-based oncolytic therapy are messenger RNA (mRNA)-based oncolytic therapy, small interfering RNA (siRNA)-based oncolytic therapy, micro RNA (miRNA)-based oncolytic therapy, and other therapy types. Messenger RNA (mRNA)-based oncolytic therapy involves using synthetic mRNA molecules designed to stimulate the immune system or directly induce tumor cell death, providing a targeted and adaptable approach to cancer treatment. These therapies are administered via intravenous, intratumoral, and other routes, and are applied in breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other indications. Key end-users include hospitals, cancer research institutes, specialty clinics, and related healthcare facilities.

The ribonucleic acid (RNA)-based oncolytic therapy market research report is one of a series of new reports that provides ribonucleic acid (RNA)-based oncolytic therapy market statistics, including the ribonucleic acid (RNA)-based oncolytic therapy industry global market size, regional shares, competitors with the ribonucleic acid (RNA)-based oncolytic therapy market share, detailed ribonucleic acid (RNA)-based oncolytic therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the ribonucleic acid (RNA)-based oncolytic therapy industry. This ribonucleic acid (RNA)-based oncolytic therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ribonucleic acid (RNA)-based oncolytic therapy market includes revenues earned by entities through services such as clinical trials, tumor targeting, immune monitoring, patient support, and treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA)-based oncolytic therapy market also includes sales of RNA oncolytic viruses, viral vectors, delivery systems, formulations, and diagnostic kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.